Why the study?
Although COVID-19 vaccines effectively protect populations, serious adverse effects such as myocarditis have been reported in rare cases.
This case report highlights a rare occurrence of fulminant myocarditis following the first dose of mRNA-1273 vaccination in a patient with prior COVID-19, which was successfully treated with steroids and mechanical support.
Fulminant myocarditis may follow mRNA-1273; this case leaves incidence, causality, and management standards open.
Background COVID-19 vaccines have shown success in protecting people worldwide, although serious adverse effects have been reported in very rare cases. Case summary A 32-year-old male with a prior medical history of mild COVID-19 infection developed fulminant myocarditis five days after mRNA-1273 vaccination (first dose), which was confirmed using endomyocardial biopsy. He acutely developed respiratory failure and cardiogenic shock with ventricular tachycardia, but recovered completely with short-term high-dose steroid therapy and mechanical cardiac support, which is the recommended treatment for fulminant lymphocytic myocarditis. Discussion COVID-19 vaccine-induced myocarditis varies from mild to severe. In the present case, the patient was treated as for fulminant lymphocytic myocarditis and recovered relatively quickly. The mechanism of COVID-19 vaccine-associated myocarditis needs to be urgently investigated.
No takes yet. Share an insight, caveat, or question.
Horiuchi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: